Scott Edward Schaus

This inventor holds 14 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Boston University, Boston Medical Center Corporation, Northeastern University. Active years: 2015-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Scott Edward Schaus. Retrieved from https://idiyas.com/inventor/scott-edward-schaus

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 3)

% Patents Active = 85.7

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 4.7

ph-index = 2

Forward Citations = 13(Granted Patents)

Company Filing History:

Boston Medical Center Corporation

patents

2 out of 686

Northeastern University

patents

4. 1 out of 28

Fundacao Oswaldo Cruz

patents

5. 1 out of 114

Sorrento Therapeutics, Inc.

patents

6. 1 out of 16,025

University of California

patents

where one patent can have more than one assignee

Years Active: 2015-2026

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12607589 - Methods, assays and systems for detection of a target analyte (2026-04-21),

2. 12251372 - Antileishmanial compounds, compositions and use thereof (2025-03-18),

3. 11458132 - Quinolin-2(1H)-one inhibitors of Late SV40 Factor (2022-10-04),

4. 11420977 - Late SV40 (LSF) inhibitors (2022-08-23),

5. 11242353 - Heterocyclic LSF inhibitors and their uses (2022-02-08),

6. 10392398 - Inhibitors of Late SV40 Factor (LSF) as cancer chemotherapeutics (2019-08-27),

7. 10314810 - Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics (2019-06-11),

8. 10258600 - Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics (2019-04-16),

9. 9815845 - Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics (2017-11-14),

10. 9802948 - Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics (2017-10-31),

11. 9597325 - Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics (2017-03-21),

12. 9567331 - Pyridopyrimidinone inhibitors of viruses (2017-02-14),

13. 9399644 - [1,3] dioxolo [4,5-G] quinoline-6(5H)thione derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer (2016-07-26),

14. 9175001 - [1,3] dioxolo [4,5-g] [1,2,4] triazolo [1,5-a] quinoline derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer (2015-11-03),

Title: The Innovations of Scott Edward Schaus

Introduction

Scott Edward Schaus is a prominent inventor based in Boston, MA, known for his significant contributions to the field of medicinal chemistry. With a total of 13 patents to his name, Schaus has made remarkable advancements in the development of compounds aimed at treating various diseases, including cancer and leishmaniasis.

Latest Patents

Among his latest patents are the "Antileishmanial compounds, compositions and use thereof," which provides innovative solutions for combating leishmaniasis through novel compounds and compositions. Another notable patent is the "Quinolin-2(1H)-one inhibitors of Late SV40 Factor," which focuses on compositions and methods for treating cancer, particularly hepatocellular carcinoma (HCC). This invention highlights the use of small-molecule compounds to inhibit tubulin acetylation, thereby affecting cell migration and compaction.

Career Highlights

Schaus has had a distinguished career, working at esteemed institutions such as Boston University and Northeastern University. His research has significantly impacted the scientific community, particularly in the areas of cancer treatment and infectious diseases.

Collaborations

Throughout his career, Schaus has collaborated with notable colleagues, including Ulla Hansen and Joshua A Bishop, contributing to a rich exchange of ideas and innovations in his field.

Conclusion

Scott Edward Schaus exemplifies the spirit of innovation in medicinal chemistry, with his patents paving the way for new treatments and therapies. His work continues to inspire future advancements in the medical field.

Profile summary based on public USPTO records.